v3.26.1
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue $ 5,418       $ 5,418   $ 5,314
Drug product revenue recognized (1,474)   $ 1,348   2,264 $ 4,088  
Related cost of goods sold 2   85   4,108 337  
Other long-term liabilities 67       67   82
Europe [Member] | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized   $ 3,300          
Accrued liabilities   3,800          
Related cost of goods sold   3,300          
Drug Product Revenue, Net [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized (1,577)   1,215   1,915 3,811  
Drug Product Revenue, Net [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized (1,600)   1,200   1,900 3,800  
Drug Product Revenue, Net [Member] | Europe [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 1,358   1,171   7,041 1,986  
Drug Product Revenue, Net [Member] | Europe [Member] | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Burdened manufacturing costs   900          
Drug Product Revenue, Net [Member] | Japan [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized (2,935)   44   (5,126) 1,825  
Accrued liabilities 2,900       2,900   1,600
Drug Product Revenue, Net [Member] | API Shipment [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized   2,900   $ 1,800 2,200    
Bulk Drug Product [Member] | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue   $ 6,200          
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         800    
Accrued liabilities 2,300       2,300   $ 5,400
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member] | Royalty Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Royalty revenue recognized as drug product revenue $ 1,200   $ 1,400   $ 2,900 $ 2,000